Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Abstract Text:

Ruben Niesvizky,Tara Naib,Paul J Christos,David Jayabalan,Jessica R Furst,Jessica Jalbrzikowski,Faiza Zafar,Tomer Mark,Richard Lent,Roger N Pearse,Scott Ely,John P Leonard,Madhu Mazumdar,Selina Chen-Kiang,Morton Coleman,

Data on 72 patients receiving lenalidomide/dexamethasone for multiple myeloma (MM) was used to determine the factors that are associated with lenalidomide-induced myelosuppression. Eight of 14 patients with grade > or =3 myelosuppression had baseline creatinine clearance (CrCl) < or =0.67 ml/s. Kaplan-Meier analysis by log-rank test demonstrated a significant association (P < 0.0001) between renal insufficiency and time to myelosuppression (hazard ratio = 8.4; 95% confidence interval 2.9-24.7, P = 0.0001). Therefore, CrCl is inversely associated with significant myelosuppression. Caution should be exercised when lenalidomide therapy is commenced and CrCl should be incorporated as a determinant of the initial dosing of lenalidomide in MM patients.

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Publishing Authors By Initials

R Niesvizky,T Naib,PJ Christos,D Jayabalan,JR Furst,J Jalbrzikowski,F Zafar,T Mark,R Lent,RN Pearse,S Ely,JP Leonard,M Mazumdar,S Chen-Kiang,M Coleman,

For similar diagnosis: prognosis: treatment outcome research abstracts see: diagnosis: prognosis: treatment outcome research

PUBMED ID PMID:

MEDLINE DATE:

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: British journal of haematology

VOLUME: 138

Page Numbers: 640-3

Journal Abbreviation: Br. J. Haematol.

ISSN: 0007-1048

DAY: 3

MONTH: Sep

YEAR: 2007

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 372544

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Keywords Mesh Terms:

KEYWORDS: Treatment Outcome

MESH TERMS: chemically induced

Chemical & Substance for Abstract: Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy. Information

Substance Name: Creatinine

Registry Number: 60-27-5

Grant and Affiliation Information for Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.

AFFILIATION: Center of Excellence for Lymphoma and Myeloma, Division of Hematology and Medical Oncology, Weill Medical College of Cornell University, New York Presbytarian Hospital-Cornell Medical Center, New York, NY 10021, USA. run9001@med.cornell.edu

Country: England

AGENCY: United States NCI

GRANT: CA109260-01

ACRONYM: CA

MEDLINETA: Br J Haematol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy Related Publications

• Ability to Exceed a Training Threshold During Tennis Activity in Persons with Physical Disabilities: 2279: Board #192 June 1 8:00 AM -9:30 AM.
• Accuracy, repeatability, and reproducibility of Artemis very high-frequency digital ultrasound arc-scan lateral dimension measurements.
• An increase in DNA double-strand breaks, induced by Ku70 depletion, is associated with human papillomavirus 16 episome loss and de novo viral integration events.
• Antigenicity of the Aeromonas salmonicida maltose-inducible outer membrane porin (maltoporin) and a hybrid protein derived from it.
• Clustering of hydatid infection in macropodids.
• Commentary: Is epidemiology really dead, anyway? A look back at Kenneth Rothman's 'The rise and fall of epidemiology, 1950-2000 AD'.
• DNA methylation-dependent silencing of CST6 in human breast cancer cell lines.
• Dissecting the molecular mechanisms of cancer through bioinformatics-based experimental approaches.
• Epirubicin for breast cancer during pregnancy: a case report.
• Hepatic overexpression of glycerol-sn-3-phosphate acyltransferase 1 in rats causes insulin resistance.
• High-frequency ultrasonic imaging of the anterior segment using an annular array transducer.
• How do I fatten thee? Let me count the ways...
• Increased oxidative stress is associated with balanced increases in hepatocyte apoptosis and proliferation in glycerol-3-phosphate acyltransferase-1 deficient mice.
• Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapy.
• Methylation-dependent silencing of CST6 in primary human breast tumors and metastatic lesions.
• Modification of the aerobic cytotoxicity of etanidazole.
• Molecular cloning and nucleotide sequence analysis of the maltose-inducible porin gene of Aeromonas salmonicida.
• Mutagenesis of rat acyl-CoA synthetase 4 indicates amino acids that contribute to fatty acid binding.
• NAD(+) and axon degeneration revisited: Nmnat1 cannot substitute for Wld(S) to delay Wallerian degeneration.
• Not credible: a subversion of science by the pharmaceutical industry. Commentary on A global comparison regarding patient access to cancer drugs (Ann Oncol 2007; 18 Suppl 3: pp 1 75).
• Overexpression of rat long chain acyl-coa synthetase 1 alters fatty acid metabolism in rat primary hepatocytes.
• Precocious development of hydatid cysts in a macropodid host.
• Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid.
• Promoting bicycle helmet wearing by children using non-legislative interventions: systematic review and meta-analysis.
• Purification of immunoglobulins from chicken sera by thiophilic gel chromatography.
• Questioning specialists' attitudes to breast cancer follow-up in primary care.
• Recruitment and retention of children in longitudinal research.
• Regulation of Triglyceride Metabolism. II. Function of mitochondrial GPAT1 in the regulation of triacylglycerol biosynthesis and insulin action.
• Treatment with 2-AAF blocks the small hepatocyte-like progenitor cell response in retrorsine-exposed rats.
• Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.